Publications

Authors:

de Marinis, Filippo; Ardizzoni, Andrea; Fontanini, Gabriella; Grossi, Francesco; Cappuzzo, Federico; Novello, Silvia; Santo, Antonio; Lorusso, Vito; Cortinovis, Diego; Iurlaro, Monica; Galetta, Domenico; Gridelli, Cesare; Milella, Michele

Title:

Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study

Year:

2014

Type of item:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Language:

Inglese

Format:

A Stampa

Referee:

No

Name of journal:

CLINICAL LUNG CANCER

ISSN of journal:

1525-7304

N° Volume:

15

Number or Folder:

5

Page numbers:

338-345

Keyword:

Chemotherapy; EGFR; Erlotinib; NSCLC; Third-line; Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Italy; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Receptor Protein-Tyrosine Kinases; ras Proteins

Short description of contents:

Introduction/background: Patients with advanced NSCLC who experience disease progression after second-line therapy might receive further active treatment. LIFE was an Italian cohort multicenter observational study composed of a cross-sectional and a longitudinal phase. Patients and methods: In the longitudinal phase, described here, the primary aim was to determine the proportion of patients receiving third-line therapy among those who received second-line active treatment according to clinical practice. The proportion of patients receiving further treatment lines was also estimated. Results: The longitudinal phase was conducted between January and August 2012. Of 464 patients who began second-line therapy outside of clinical trials within the baseline evaluation, 56 (12.1%) were still receiving second-line therapy at the end of the observation period and 17 (3.7%) withdrew during or after second-line therapy. Of the remaining 391 patients, 158 (40.4%) received third-line treatment outside of clinical trials: 93 received a third-line chemotherapy and 65 a targeted agent. The main reason for interrupting third-line treatment was disease progression or death. During the same observation period, 25 of 113 patients who completed a third-line therapy received a fourth line of treatment. From diagnosis of NSCLC to the end of observation, biomarkers were tested in 323 patients (59.7%): epidermal growth factor receptor mutations in 315 (58.2%), Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) mutations in 83 (15.3%) and Anaplastic lymphoma kinase (ALK) translocation in 84 (15.5%). Conclusion: In Italian clinical practice, the proportion of patients with advanced NSCLC receiving more than 2 treatment lines of therapy is not negligible.

Product ID:

127172

Handle IRIS:

11562/1066733

Last Modified:

March 28, 2023

Bibliographic citation:

de Marinis, Filippo; Ardizzoni, Andrea; Fontanini, Gabriella; Grossi, Francesco; Cappuzzo, Federico; Novello, Silvia; Santo, Antonio; Lorusso, Vito; Cortinovis, Diego; Iurlaro, Monica; Galetta, Domenico; Gridelli, Cesare; Milella, Michele, Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study «CLINICAL LUNG CANCER» , vol. 15 , n. 5 , 2014 , pp. 338-345

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo